Last reviewed · How we verify
Nebivolol (NEB)
Nebivolol is a selective beta-1 adrenergic receptor antagonist that also has vasodilatory properties through nitric oxide release.
Nebivolol is a selective beta-1 adrenergic receptor antagonist that also has vasodilatory properties through nitric oxide release. Used for Hypertension, Heart failure with reduced ejection fraction.
At a glance
| Generic name | Nebivolol (NEB) |
|---|---|
| Sponsor | Mylan Bertek Pharmaceuticals |
| Drug class | Beta-1 selective adrenergic receptor antagonist |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nebivolol blocks beta-1 adrenergic receptors on the heart, reducing heart rate and contractility to lower blood pressure and cardiac workload. Unlike traditional beta-blockers, it also possesses vasodilatory properties mediated by nitric oxide release in endothelial cells, providing additional cardiovascular benefits. This dual mechanism makes it particularly useful in hypertension management with improved tolerability.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
Common side effects
- Fatigue
- Dizziness
- Headache
- Bradycardia
- Hypotension
Key clinical trials
- Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients (PHASE4)
- Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |